Skeletal muscle regeneration and Sarcopenia therapy: Focusing on the role of GFX
Project/Area Number |
15K12699
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Applied health science
|
Research Institution | Nagoya University |
Principal Investigator |
KUZUYA Masafumi 名古屋大学, 未来社会創造機構, 教授 (10283441)
|
Research Collaborator |
INOUE Aiko 名古屋大学, 大学院医学系研究科, 大学院生
KIMURA Kaoru 名古屋大学, 大学院医学系研究科, 客員研究者
GOTO Hiroki 名古屋大学, 医学部附属病院, 医員 (50770913)
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 加齢 / 障害 / 骨格筋幹細胞 / 骨格筋リモデリング / 老化 / サルコペニア / 動物 |
Outline of Final Research Achievements |
We have the first time observed that cardiotoxin-injury results an increase in new growth factor-x (GFX) gene and protein expression in the muscles. Neutralizing antibody against GFX impaired muscle function recovery and aggravated interstitial fibrosis and muscle stem cell homing into the muscle in response to cardiotoxin; these changes were mitigated by the mouse recombinant GFX intervention. These findings suggest that GFX might be new therapeutic target for the injury-related muscle disease like Sarcopenia and frailty.
|
Report
(3 results)
Research Products
(8 results)
-
[Journal Article] Exercise Restores Muscle Stem Cell Mobilization and Regenerative Capacity and Muscle Metabolic Alterations via Adiponectin/AdipoR1 Activation in SAMP10 mice.2016
Author(s)
Inoue A, Cheng XW, Huang Z, Hu L, Kikuchi R, Jiang H, Piao L, Sasaki T, Itakura K, Wu H, Zhao G, Lei Y, Yang G, Zhu E, Li X, Sato K, Koike T, Kuzuya M.
-
Journal Title
Journal of Cachexia, Sarcopenia and Muscle.
Volume: -
Issue: 3
Pages: 370-385
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
-
-
-
-
-